The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII-/- mice

Michelle A. Sallin, Xiaoyu Zhang, Edward C. So, Erin Burch, Ling Cai, Wei Lin, Andrei I. Chapoval, Scott E. Strome

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Agonistic monoclonal antibodies (mAbs) directed against the co-signaling molecule CD137 (4-1BB) elicit potent anti-tumor immunity in mice. This anti-tumor immunity has traditionally been thought to result from the ability of the Fab portion of anti-CD137 to function as an analog for CD137L. Although binding of CD137 by anti-CD137 mAbs has the potential to cross-link the Fc fragments, enabling Fc engagement of low to moderate affinity Fc gamma receptors (FcγR), the relative import of such Fc-FcγR interactions in mediating anti-CD137 associated anti-tumor immunity is unknown. We studied the ability of a rat anti-mouse CD137 mAb (2A) to mediate the anti-tumor response against the EL4E7 lymphoma in WT and FcγR-/- strains. 2A-treated FcRγ-/- mice had improved anti-tumor immunity against EL4E7, which could be completely recapitulated in FcγRIII -/- animals. These improved anti-tumor responses were associated with increased splenic CD8β T cell and dendritic cell (DC) populations. Furthermore, there was an increase in the number of DCs expressing high levels of the CD40, CD80, and CD86 molecules that are associated with more effective antigen presentation. Our results demonstrate an unexpected inhibitory role for FcγRIII in the anti-tumor function of anti-CD137 and underscore the need to consider antibody isotype when engineering therapeutic mAbs.

Original languageEnglish (US)
Pages (from-to)947-958
Number of pages12
JournalCancer Immunology, Immunotherapy
Issue number9
StatePublished - Sep 2014
Externally publishedYes


  • 4-1BB
  • CD137
  • Cancer
  • Dendritic cell
  • Fcγ receptor
  • Monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII-/- mice'. Together they form a unique fingerprint.

Cite this